Filtered By:
Condition: Thrombosis
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 1175 results found since Jan 2013.

In Potential Stroke Patients on Warfarin, the International Normalized Ratio Predicts Ischemia
Conclusions: Sub-therapeutic INR and atrial fibrillation are strongly associated with ischemia in patients on warfarin presenting with acute neurologic symptoms. Ischemia is far less likely in patients with an INR of ≥2 and rare in those with an INR ≥3.6. This study shows that the INR value of a patient on warfarin can help stratify patients’ risk for acute ischemic stroke and guide further neurologic imaging and workup.Cerebrovasc Dis Extra 2017;7:111 –119
Source: Cerebrovascular Diseases Extra - October 25, 2017 Category: Neurology Source Type: research

Prevalence, Mechanisms, and Management of Ischemic Stroke in Heart Failure Patients
Semin Neurol DOI: 10.1055/s-0041-1726329Heart failure (HF) and stroke, two of the major causes of death worldwide, are closely associated. Although atrial fibrillation (AF), which occurs in more than half of patients with HF, is a major risk factor for stroke, there is a great deal of evidence that HF itself increases the risk of stroke independent of AF. The main mechanism of stroke appears to be thromboembolism. However, previous studies have failed to demonstrate the benefit of warfarin in patients with HF without AF, as the benefit of stroke prevention was counteracted by the increased incidence of major bleeding. Rece...
Source: Seminars in Neurology - April 13, 2021 Category: Neurology Authors: Seol, Hyeyoung Kim, Jong S. Tags: Review Article Source Type: research

Apixaban: A New Factor Xa Inhibitor for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation
Atrial fibrillation (AF) is an independent risk factor for ischemic stroke occurrence, severity, recurrence, and mortality. Anticoagulation therapy for the prevention of thromboembolism is critical in patients with AF who are at risk of stroke. Warfarin has been an efficacious anticoagulant for this purpose, but its use has been limited by frequent laboratory monitoring, drug interactions, unpredictable individual response, delayed onset of action, and bleeding. Apixaban is the second oral direct selective factor Xa inhibitor approved for the prevention of stroke/systemic embolism in patients with nonvalvular AF. It was si...
Source: Cardiology in Review - June 6, 2013 Category: Cardiology Tags: New Therapy Update Source Type: research

Stroke prevention in atrial fibrillation—An Asian stroke perspective
Despite relatively lower prevalence of atrial fibrillation (AF) in Asians (~1%) than in Caucasians (~2%), Asia has a much higher overall disease burden because of its proportionally larger aged population. For example, on the basis of reported age-adjusted prevalence rates and projected population figures in China, there will be an estimated 5.2 million men and 3.1 million women with AF older than 60 years by year 2050. Stroke is a disabling complication of AF that is of increasing cause for concern in Asians patients. Implementing consensus expert recommendations for managing stroke risk in patients with AF can considerab...
Source: Heart Rhythm - March 18, 2013 Category: Cardiology Authors: Hung-Fat Tse, Yong- Jun Wang, Moheeb Ahmed Ai-Abdullah, Annette B. Pizarro-Borromeo, Chern-En Chiang, Rungroj Krittayaphong, Balbir Singh, Amit Vora, Chun-Xue Wang, Mohammad Zubaid, Andreas Clemens, Paul Lim, Dayi Hu Tags: Contemporary Review--Associate Editor: Sami Viskin Source Type: research

Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation
Opinion statement Atrial fibrillation (AF) is the most common sustained cardiac rhythm disorder, which can potentially increases the risk of stroke by five-fold, thus, resulting in high public healthcare burden. Stroke prevention is vital in the management of AF patients. Vitamin K antagonists (VKA, eg, warfarin) have been the mainstay treatment to prevent ischemic stroke and systemic thromboembolism in AF patients for several decades. Despite the efficacy of warfarin, its limitations have recently driven the advent of some new antithrombotic agents, the non-VKA oral anticoagulant (NOACs, including dabigatran, ri...
Source: Current Treatment Options in Neurology - February 11, 2015 Category: Neurology Source Type: research

Stroke prevention in atrial fibrillation: an update on current management strategies.
Authors: Hall T, Stanton T, Wang WY, Ng AC Abstract Stroke attributed to atrial fibrillation (AF) confers significant morbidity and mortality. In the past, warfarin has been the only successful stroke prevention agent available. However, it is often underutilized due to its well-known limitations, leaving many patients without adequate stroke protection. The last decade has seen significant strides forward in the field of anticoagulation for AF. The development of several novel oral anticoagulants that have superior efficacy, improved safety profile and fixed doses without the need for regular monitoring make them ...
Source: Panminerva Medica - June 4, 2015 Category: Journals (General) Tags: Panminerva Med Source Type: research

Underutilization of warfarin for stroke prophylaxis in patients with atrial fibrillation or atrial flutter in Korea.
CONCLUSIONS: A high portion of AF/AFL patients with CHADS2 score ≥2 were undertreated with warfarin. As ischemic stroke is one of the leading causes of death in Korea, a more aggressive approach to prevent stroke in patients with AF/AFL is required. PMID: 26242197 [PubMed - as supplied by publisher]
Source: Journal of Cardiology - August 1, 2015 Category: Cardiology Authors: Lee IH, Kim H, Je NK Tags: J Cardiol Source Type: research

Factors Associated with Thrombolysis Outcome in Ischemic Stroke Patients with Atrial Fibrillation
In this study, we investigated factors that influence the effect of intravenous thrombolysis in these patients. Our results showed that thrombolysis was independently associated with a favorable outcome (P < 0.001) and did not influence the mortality of AF-related ischemic stroke, although it increased the risk of hemorrhage within 24 h after treatment. Risk factors for a poor outcome at admission were: heart failure (P = 0.045); high systolic pressure (P = 0.039); high blood glucose (P = 0.030); and a high National Institutes of Health Stroke Scale (NIHSS) score (P < 0.001). Moreover, high systolic pressur...
Source: Neuroscience Bulletin - March 7, 2016 Category: Neuroscience Source Type: research

Abstract 160: Impact of Medication Adherence on Risk of Stroke, Major Bleeding and Other Outcomes in Atrial Fibrillation Patients Using Novel Oral Anticoagulants (Dabigatran and Rivaroxaban) Session Title: Poster Session II
Conclusion: In our sample, adherence to NOACs was associated with a reduction in stroke and DVTPE risk but did not substantially increase bleeding risk. Further studies with newer NOACs are warranted.
Source: Circulation: Cardiovascular Quality and Outcomes - March 31, 2017 Category: Cardiology Authors: Deshpande, C. G., Willey Temkin, C., Laforge, R., Kogut, S. Tags: Session Title: Poster Session II Source Type: research

Factors associated with non –vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Conclusions In contemporary clinical practice, up to three-fourths of patients with new-onset AF are now initially treated with a NOAC for stroke prevention. Those selected for NOAC treatment had lower stroke and bleeding risk profiles, were more likely treated by cardiologists, and had higher socioeconomic status. Trial registration clinicaltrials.gov Identifier: NCT01701817
Source: American Heart Journal - April 25, 2017 Category: Cardiology Source Type: research

Stroke Severity in Patients on Non-Vitamin K Antagonist Oral Anticoagulants with a Standard or Insufficient Dose.
CONCLUSION:  Use of warfarin with a therapeutic intensity or standard-dosed NOACs was associated with a relatively mild stroke in the patients with NVAF. PMID: 30453351 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - November 19, 2018 Category: Hematology Authors: Jung YH, Choi HY, Lee KY, Cheon K, Han SW, Park JH, Cho HJ, Park HJ, Nam HS, Heo JH, Lee HS, Kim YD Tags: Thromb Haemost Source Type: research

Stroke and Systemic Thromboembolism according to CHA < sub > 2 < /sub > DS < sub > 2 < /sub > -VASc Score in Contemporary Korean Patients with Atrial Fibrillation
CONCLUSION: Contemporary AF patients have a stroke rate about one-fifth that in OAC-naïve AF patients and exhibit different stroke risk factors.STUDY REGISTRATION: ClinicalTrials.gov (NCT02786095).PMID:35352882 | DOI:10.3349/ymj.2022.63.4.317
Source: Yonsei Medical Journal - March 30, 2022 Category: Universities & Medical Training Authors: Kyung Bae Lee Tae-Hoon Kim Junbeom Park Jin-Kyu Park Ki-Woon Kang Jun Kim Hyung Wook Park Eue-Keun Choi Jin-Bae Kim Young Soo Lee Jaemin Shim Boyoung Joung Source Type: research